foxo1

FOXO1-IN-3 is a highly-selective, orally active inhibitor of FOXO1 that diminishes hepatic glucose production and enhances insulin sensitivity and glucose regulation in db/db mice, all without inducing weight gain [1].

Hymenidin, an alkaloid isolated from the Okinawan sponge Hymeniacidon sp. is a 5-hydroxytryptaminergic receptor antagonist and voltage-gated potassium channel inhibitor with potential antiprotozoal effects.It selectively binds to FOXO1 DNA and reduces depolarization-induced elevation of cellular calcium.

AS1842856, a cell-permeable inhibitor, can block the transcription activity of Foxo1 (IC50: 33 nM). It can directly bind to the active Foxo1, but not the Ser256-phosphorylated form.

Kihadanin B can repress the adipogenesis by decreasing lipid accumulation through the suppression of the Akt-FOXO1-PPARγ axis in 3T3-L1 adipocytes.

Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, it may be a potent compound for preventing/counteracting diabetic e

JY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.

Acetyl-Exenatide, an acetylated derivative of Exenatide, mirrors insulin's functionality and is utilized in type 2 diabetes research. It promotes Th17 differentiation, inhibits Tregs differentiation, and downregulates PI3K/Akt/FoxO1 phosphorylation [1].

PFI-90, a selective histone demethylase (KDM3B) inhibitor, targets PAX3-FOXO1 action and demonstrates potential antitumor activity. It induces apoptosis and myogenic differentiation, leading to increased cell death.

Oxypaeoniflorin a monoterpene glycoside compound isolated from Paeoniae, is an antioxidant, is neuroprotective and anti-inflammatory.

MIR96-IN-1 selectively inhibits biogenesis of microRNA-96, upregulating a protein target (FOXO1) and inducing apoptosis in cancer cells.

AS1708727 is a Foxo1 inhibitor, exerting anti-hypertriglyceridemic and anti-diabetic effects by improving triglyceride and blood glucose metabolism at the gene expression level.